Alexander’s(ALX)
Search documents
Alexander's (ALX) Tops Q3 FFO and Revenue Estimates
ZACKS· 2024-11-04 15:55
Earnings Performance - Alexander's reported quarterly FFO of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share, representing a 10.51% surprise [1] - This compares to FFO of $3.63 per share a year ago [1] - The company has surpassed consensus FFO estimates two times over the last four quarters [2] Revenue Performance - Alexander's posted revenues of $55.68 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.07% [2] - This compares to year-ago revenues of $55.41 million [2] - The company has topped consensus revenue estimates three times over the last four quarters [2] Stock Performance - Alexander's shares have added about 5.9% since the beginning of the year, underperforming the S&P 500's gain of 20.1% [3] Future Outlook - The current consensus FFO estimate is $2.79 on $53.5 million in revenues for the coming quarter and $13.65 on $221.9 million in revenues for the current fiscal year [7] - The estimate revisions trend for Alexander's is mixed, translating into a Zacks Rank 3 (Hold) [6] Industry Context - The REIT and Equity Trust - Other industry is currently in the top 27% of the 250 plus Zacks industries [8] - The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - DiamondRock Hospitality (DRH) is expected to post quarterly earnings of $0.26 per share, representing no change from the year-ago quarter [9] - DiamondRock Hospitality's revenues are expected to be $286.98 million, up 3.8% from the year-ago quarter [10]
Alexander's Announces Third Quarter Financial Results
GlobeNewswire News Room· 2024-11-04 14:16
PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER’S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported: Third Quarter 2024 Financial Results Net income for the quarter ended September 30, 2024 was $6.7 million, or $1.30 per diluted share, compared to $10.8 million, or $2.10 per diluted share for the quarter ended September 30, 2023. Funds from operations (“FFO”) (non-GAAP) for the quarter ended September 30, 2024 was $14.6 million, o ...
Alexander’s(ALX) - 2024 Q3 - Quarterly Report
2024-11-04 13:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended:September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-06064 ALEXANDERS INC (Exact name of registrant as specified in its charter) Delaware 51-0100517 | --- | --- | |----------- ...
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
GlobeNewswire News Room· 2024-11-01 21:30
Core Insights - ALX Oncology announced that results from a Phase 1b/2 trial of evorpacept in combination with zanidatamab for HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium in December 2024 [1][2] Group 1: Clinical Trial Details - The Phase 1b/2 clinical trial is an open-label, multicenter study (NCT05027139) assessing evorpacept and zanidatamab as a treatment for HER2-expressing breast cancer and other cancers [2] - The presentation will include the title "Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study" with Abstract Number SESS-2007 [2] - The presentation is scheduled for December 12, 2024, from 7:00 a.m. to 8:30 a.m. CST at the Henry B. Gonzalez Convention Center, San Antonio, Texas [2] Group 2: Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and improve patient survival [3] - The lead therapeutic candidate, evorpacept, is positioned as a potential cornerstone therapy for future immuno-oncology treatments and is being evaluated in multiple ongoing clinical trials across various cancer indications [3]
Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
GlobeNewswire News Room· 2024-10-22 17:45
PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens. Vornado Realty Trust (NYSE: VNO), the manager which conducts Alexander’s operations, announced it will host its quarterly earnings conference call and an audio ...
Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.
Newsfile· 2024-10-11 18:12
Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESOctober 11, 2024 2:12 PM EDT | Source: ALX Resources Corp.Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3) ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6 ...
Alexander's Completes $400 Million Refinancing of 731 Lexington Avenue Office Condominium
GlobeNewswire News Room· 2024-09-30 20:27
Core Viewpoint - Alexander's, Inc. has successfully completed a $400 million refinancing of the office condominium portion of 731 Lexington Avenue, significantly reducing its interest rate and extending the loan maturity [1] Group 1: Loan Details - The new loan is an interest-only loan with a fixed rate of 5.045% and matures in October 2028 [1] - The refinancing replaces a prior $490 million loan that had an interest rate tied to the Prime rate, currently at 8.00%, and was set to mature in October 2024 [1] - The new loan allows for prepayment at Alexander's option without penalty starting in October 2026 [1] Group 2: Company Overview - Alexander's, Inc. is a real estate investment trust (REIT) that owns five properties in New York City [1]
Best Income Stocks to Buy for September 18th
ZACKS· 2024-09-18 13:50
Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 18th:Alexander's (ALX) : This real estate investment trust which is engaged in leasing, managing, developing and redeveloping properties, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.5% over the last 60 days.This Zacks Rank #1 (Strong Buy) company has a dividend yield of 7.4%, compared with the industry average of 4.2%.J. Sainsbury (JSAIY) : This leading ...
New Strong Buy Stocks for September 18th
ZACKS· 2024-09-18 11:36
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:SharkNinja, Inc. (SN) : This is a diversified, product design and technology company which creates lifestyle solutions through products for consumers, has seen the Zacks Consensus Estimate for its current year earnings increasing 10.7% over the last 60 days.Alexander's (ALX) : This real estate investment trust which is engaged in leasing, managing, developing and redeveloping properties, has seen the Zacks Consensus Estimate for its cur ...
Best Income Stocks to Buy for September 13th
ZACKS· 2024-09-13 09:50
Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 13:BancFirst Corporation (BANF) : This bank holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% the last 60 days.This Zacks Rank #1 company has a dividend yield of 1.6%, compared with the industry average of 0.7%.Alexander's, Inc. (ALX) : This real estate investment trust has witnessed the Zacks Consensus Estimate for its current year earnings ...